Product information and disease descriptionPlace of product in therapyDisease description
Diagnosis
7 evidence topics · 10 sources
Establishing the diagnosis: clinical findings and molecular genetic testing
“The diagnosis is usually confirmed through identification of an increased CAG repeat length in the huntingtin gene in a patient with clinical features of the condition. Though diagnosis is usually straightforward, unusual presentations can occur, and it can be difficult to know when someone has transitioned from being an asymptomatic carrier into the disease state.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinical motor diagnosis: diagnostic confidence level
“Huntington's disease (HD) is currently diagnosed based on the presence of motor signs indicating 99% "diagnostic confidence" for HD. Recent advances in the understanding of HD natural history and neurobiology indicate that disease-related brain changes begin at least 12 to 15 years before the formal diagnosis based on motor onset.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“with the gene mutation for Huntington's disease but without a motor diagnosis (a rating below 4 on the diagnostic confidence level from the 15-item motor assessment of the Unified Huntington's Disease Rating Scale)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Staging: Huntington's Disease Integrated Staging System
“The Huntington's Disease Integrated Staging System (HD-ISS) comprises a biological research definition and evidence-based staging centred on biological, clinical, and functional assessments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“If there are signs of neurodegeneration, evidenced by atrophy of the caudate or putamen, individuals are assigned to stage 1. If disease signs are measurable by the TMS or Symbol Digit Modalities Test (SDMT), they are classified as stage 2. Finally, if there is an impact on daily functioning as assessed by the Total Functional Capacity (TFC) or the Independence Scale, individuals are assigned to stage 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinical motor diagnosis, or a Diagnostic Confidence Level (DCL) of 4, corresponds to the latter part of HD-ISS stage 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Predictive genetic testing in at-risk individuals
Biomarkers: plasma neurofilament light protein
“Mean concentrations of NfL in plasma at baseline were significantly higher in HTT mutation carriers than in controls (3·63 [SD 0·54] log pg/mL vs 2·68 [0·52] log pg/mL, p<0·0001) and the difference increased from one disease stage to the next.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 104 individuals with premanifest Huntington's disease, NfL concentration in plasma at baseline was associated with subsequent clinical onset during the 3-year follow-up period (hazard ratio 3·29 per log pg/mL, 95% CI 1·48-7·34, p=0·0036).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote